Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients

Inclusion Criteria:

* Histologically confirmed stage II, III or IV melanoma patients.
* Tumor expression of Melan-A.
* Human leukocyte antigen-A2 (HLA-A2) positive.
* Expected survival of at list 3 months.
* Karnofsky scale performance status of 70 % or more.
* Age ≥ 18 years.
* Able to give a written informed consent.
* The following laboratory results:

Hemoglobin ≥ 100g/L, Neutrophil count ≥ 1.5 x 109/L, Lymphocyte count ≥ 0.5 x 109/L, Platelet count ≥ 100 x 109/L, Serum creatinine ≤ 2 mg/dL (0.18mmol/L), Serum bilirubin ≤ 2mg/dL (0.034mmol/L), Granulocyte count \> 2.5x109/L, Aspartate Amino Transférase (ASAT), Alanine Amino Transferase (ALAT) \< 2.5 x upper limit of normal, Activated Partial Thromboplastin Time (aPTT) within the normal ranges ±25%, Thromplastin (TP) ≥ 80%

Exclusion Criteria:

* Clinically significant heart disease.
* Serious illness, eg. serious infections requiring antibiotics, uncontrolled peptic ulcer, or central nervous system disorders.
* History of immunodeficiency disease or autoimmune disease.
* Metastatic disease to the central nervous system, unless treated and stable.
* Known HIV positivity.
* Known seropositivity for hepatitis B surface antigen.
* Concomitant treatment with steroids, antihistamine drugs. Topical or inhalation steroids are permitted.
* Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.
* Pregnancy or lactation.
* Women of childbearing potential not using a medically acceptable means of contraception.
* Psychiatric or addictive disorders that may compromise the ability to give informed consent.
* Lack of availability of the patient for immunological and clinical follow-up assessment.
* Coagulation or bleeding disorders.
* Kidney dysfunction with creatinine \> 2 X the upper limit of the normal value.
* Reported strong (allergic) reactions to previous vaccination.